Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.
Nabriva’s lead pleuromutilin product candidate, lefamulin, is being studied in two global, registrational Phase 3 clinical trials for the treatment of moderate to severe ... More >>
Nabriva Announces Terms of Rights Offering
|VIENNA, Austria and KING OF PRUSSIA, Pa., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV) announced today the terms of its rights offering for up to 588,127 common shares, including common shares represented by American Depositary Shares (ADSs), to its existing common shareholders and ADS holders. The record date of the rights offering is November 29, 2016. Holders of common shares on the record date are entitled to exercise statutory rights to subscribe for new common ... |
Nabriva Announces Change in Record Date for Planned Rights Offering
|VIENNA, Austria and KING OF PRUSSIA, Pa., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (Nabriva) (NASDAQ:NBRV), an Austrian stock corporation, announced today that it has changed the record date for its previously announced planned rights offering from November 22, 2016 to November 29, 2016. Holders of common shares on the new record date will be entitled to exercise non-transferable statutory pre-emptive rights to subscribe for new common shares to maintain their proportionate ow... |
Nabriva Reports Third Quarter 2016 Financial Results
|Reiterates expectation of top-line data from both CABP phase 3 trials in the second half of 2017.
VIENNA, Austria and KING OF PRUSSIA, Pa., Nov. 16, 2016 (GLOBE NEWSWIRE) -- (NASDAQ:NBRV) – Nabriva Therapeutics AG, a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today reported its financial results for the three and nine months ended September ... |